Integrated Two-Analyte Population Pharmacokinetics Model of Patritumab Deruxtecan (HER3-DXd) Monotherapy in Patients with Solid Tumors [0.03%]
单药patritumab deruxtecan（HER3-DXd）治疗实体瘤患者的两种生物标志物综合群体药代动力学模型
Yuan Xu,Mark Lee,Rujuta Joshi et al.
Yuan Xu et al.
Background and objective: Patritumab deruxtecan (HER3-DXd, also known as MK-1022) is an antibody-drug conjugate comprising a fully human monoclonal antibody against human epidermal growth factor receptor 3 (HER3) attached...
Population Pharmacokinetics of Elexacaftor, Tezacaftor and Ivacaftor in a Real-World Cohort of Adults with Cystic Fibrosis [0.03%]
依拉环素、泰泽环素和艾伏环素在成人囊性纤维化真实世界队列中的群体药代动力学特征
Paulette Magnas,Naïm Bouazza,Frantz Foissac et al.
Paulette Magnas et al.
Background and objectives: Elexacaftor-tezacaftor-ivacaftor (ETI), a combination of cystic fibrosis transmembrane conductance regulator (CFTR) modulators, has become the therapeutic standard of care for most people with c...
Pharmacokinetics of Ivacaftor, Tezacaftor, Elexacaftor, and Lumacaftor in Special Cystic Fibrosis Populations: A Systematic Review [0.03%]
囊性纤维化特殊人群的伊伐卡托、特泽卡托、艾拉卡托和卢卡托的药代动力学：系统评价
Femke A Elzinga,Paul R V Malik,Onno W Akkerman et al.
Femke A Elzinga et al.
Background and objective: Following the development of cystic fibrosis transmembrane conductance regulator (CFTR) modulators (ivacaftor, tezacaftor, elexacaftor, and lumacaftor), the prognosis for people diagnosed with cy...
An Adult Population Pharmacokinetic Model to Simulate Subcutaneous Administration of a Fixed Dose of Furosemide in Adolescents with Heart Failure and Volume Overload [0.03%]
一项成人人群药代动力学模型模拟心力衰竭和容量负荷过重的青少年使用固定剂量呋塞米皮下给药的情况
Christoph P Hornik,Henry P Foote,Eric Kendig et al.
Christoph P Hornik et al.
Background: Subcutaneous furosemide administered with the On-Body Infusor could be useful in children with heart failure (HF) and congestion due to volume overload, but the appropriate dosing regimen is unknown. ...
A Systematic Review and Classification of the Effects of P-glycoprotein Inhibitors and Inducers in Humans, Using Digoxin, Fexofenadine, and Dabigatran as Probe Drugs [0.03%]
人类P-糖蛋白抑制剂和诱导剂作用的系统评价及分类：用毒毛旋花子苷、倍他司丁和达比加群作为探针药物的研究
Claire Coumau,Chantal Csajka
Claire Coumau
P-glycoprotein is a critical efflux transporter that may significantly affect the pharmacokinetics of various drugs by influencing their absorption, distribution and elimination. While European and American regulatory guidelines provide lis...
The Impact of Dietary Interventions on the Pharmacokinetics of Antifungal Drugs: A Systematic Review with Meta-analyses [0.03%]
饮食干预对抗真菌药物药代动力学影响的系统评价和 meta 分析
Agnieszka Wiesner-Kiełczewska,Paweł Zagrodzki,Paweł Paśko
Agnieszka Wiesner-Kiełczewska
Background and objective: Managing food-drug interactions may help to optimize the efficacy and safety of antifungal therapy. This systematic review followed Preferred Reporting Items for Systematic reviews and Meta-Analy...
Maternal-Fetal Physiologically Based Population Pharmacokinetics Model Development of Lopinavir/Ritonavir in HIV/HBV Co-infected Pregnant Women to Quantitatively Describe the Gestational PK Characteristics and Predict the Potential Disease-Drug-Drug Interaction (DDDI) [0.03%]
用于预测疾病-药物-药物相互作用的乙型肝炎和人类免疫缺陷病毒合并感染孕妇体内洛匹那韦/利托那韦群体药代动力学模型研究
Ling Song,Xuan Guo,Wei Yang et al.
Ling Song et al.
Background and objective: Lopinavir/ritonavir (LPV/r) has been widely used in HIV/HBV co-infected pregnant-women. We aim to characterize the maternal-fetal (m-f) pharmacokinetic (PK) of LPV/r and support the dose optimiza...
Prediction of Interspecies Translation for Targeting Delivery Coefficients of GalNAc-siRNA Silencing Apolipoprotein C-III Using a Mechanistic Minimal Physiologically Based Pharmacokinetic/Pharmacodynamic Model [0.03%]
基于机制的最小生理药动/药效学模型预测N-乙酰半乳糖胺-siRNA沉默载脂蛋白C-III跨物种递送系数的研究
Zhiteng Tian,Hui Luo,Yantao Chu et al.
Zhiteng Tian et al.
Background and objective: The emerging N-acetylgalactosamine-small interfering RNA (GalNAc-siRNA) conjugates lead the way for liver-targeting delivery to exert gene-silencing therapeutic effects. To facilitate the drug de...
Scoping Review of Paediatric Population Pharmacokinetic Models of Morphine [0.03%]
吗啡儿科人群药代动力学模型的综述性研究
Michael A Stokes,Noha A Kamel,Marino S Festa et al.
Michael A Stokes et al.
Objective and purpose: This scoping review aimed to summarise all available population pharmacokinetic models of morphine and its metabolites (morphine-3-glucoronide [M3G], morphine-6-glucoronide [M6G]) in children and de...
Pharmacometabolomics Detects Various Unreported Metoprolol Metabolites in Urine of (Potential) Living Kidney Donors and Kidney Transplant Recipients [0.03%]
药理代谢组学检测到潜在活体供者和肾移植受者尿液中未报告的美托洛尔代谢产物
Wietske A Heddema,Marieke A J Hof,Piotr Sosnowski et al.
Wietske A Heddema et al.
Background and objective: Metoprolol is primarily metabolized via the polymorphic cytochrome P450-2D6 (CYP2D6) enzyme, which underlies interindividual variation in conversion rates and may benefit from pharmacogenetics-dr...